HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

GSK Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

GSK Intelligence Report

Generated from 20 signals · 9 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 71%

Evidence

102 items

Sources

34

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

GSK maintains an active intelligence profile across Infectious Disease, Antifungal, Neurology, Smoking Cessation, Oncology. 20 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 71% across 9 tracked sources. Highest-priority development: Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3. Portfolio development. Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3 is an owned GSK portfolio development in Infectious Disease · Pneumococcal Vaccine.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 16, 2026

    Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Infectious Disease · Pneumococcal Vaccine · opportunity score 106

    View detail
  2. portfolio

    Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Phase III success

    View detail
  3. portfolio

    Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Phase III success

    View detail
  4. competitive

    Janssen (named in signal competitive context)

    Elevated competitive pressure

    View detail
  5. regulatory

    FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — BREXAFEMME (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — BREXAFEMME (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ZYBAN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — OJJAARA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 2035 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review. Competitiva linkage surfaces 1 competitive finding requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Janssen (named in signal competitive context)

    Moderate Confidence · 72%

    Elevated competitive pressure

    Source: FDA, Competitiva

    View evidence

  • Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Low Confidence · 0%

    Phase III success

    Source: Humanexa Signals, Pfizer, Portfolio

    View evidence

  • Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Low Confidence · 0%

    Phase III success

    Source: PubMed, Pfizer, Portfolio

    View evidence

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BREXAFEMME (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BREXAFEMME (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZYBAN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — OJJAARA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Rare Disease Drug Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BREXAFEMME (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

    Infectious Disease · COVID-19

  • Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

    Respiratory · Chronic Cough

  • FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

    Immunology · IL-23

  • Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

    Infectious Disease · Pneumococcal Vaccine

  • Phase III Trial Shows Non-Inferior Immunogenicity of PCV-Free Rotavirus Vaccine in Infants

    Infectious Disease · Vaccines

  • FDA Grants Priority Review for UTEBZI (TEBIPENEM, PIVOXIL) by GlaxoSmithKline

    Infectious Disease · Antibiotic

  • FDA Approves Supplemental Application for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

    Infectious Disease · Antifungal

  • FDA Accepts Supplement for OJJAARA (Momelotinib Dihydrochloride) by GlaxoSmithKline

    Oncology · Small Molecule

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.